Program
efinopegdutide
Also written as “Efinopegdutide”, “JNJ-64565111” and “JNJ-64565111 Dose Level 1”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 80 open or running | phase 2since Mar 23, 2018 | Jun 24, 2016 | none ahead |
| Merck | 70 open or running | phase 2since Jun 28, 2021 | Jun 28, 2021 | none ahead |
- Named in Merck’s own pipeline as
efinopegdutide (MK-6024)
, phase 2, as of Nov 2, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 24, 2016First study: phase 1 study in Diabetes Mellitus, Type 2New to Johnson & JohnsonJohnson & Johnson · NCT02862431 · 24 enrolled · Germany
- Jul 28, 2017Phase 1 study in Diabetes Mellitus, Type 2Johnson & Johnson · NCT03235219 · 39 enrolled · United States
- Mar 23, 2018Phase 2 study in ObesityJohnson & Johnson · NCT03486392 · 474 enrolled · United States, Belgium, Canada and more
- May 23, 2018Phase 1 study in Kidney Failure, ChronicJohnson & Johnson · NCT03546205 · 40 enrolled · United States
- Jun 22, 2018Phase 2 study in ObesityJohnson & Johnson · NCT03586830 · 196 enrolled · United States
- Jun 29, 2018Phase 1 study in ObesityJohnson & Johnson · NCT03586843 · 52 enrolled · United States
- Jul 10, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03606057 · 188 enrolled · United States
- Aug 2, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03618160 · 42 enrolled · Japan
- Jun 28, 2021Merck's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to MerckMerck · NCT04944992 · 145 enrolled · United States, Argentina, Australia and more
- May 17, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT05877547 · 381 enrolled · United States, Austria, Belgium and more
- Sep 18, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT06052566 · 22 enrolled · United States
- Jun 13, 20242 phase 2 studies in Non-alcoholic Fatty Liver DiseaseMerck · NCT06465186, NCT06482112
- Nov 20, 2024Phase 1 study in HealthyMerck · NCT06701305 · 48 enrolled · United States
- Feb 18, 2025Phase 1 study in HealthyMerck · NCT06836037 · 56 enrolled · China
TargetBeta
“A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alc…”NCIt, read by Claude
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| DR10624rule | Huadong Medicine | phase 3 | 6 |
| AZD9550 | AstraZeneca | phase 2 | 7 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06836037Healthy · China | 1 | Completed | Merck | Feb 2, 2023 | 56 |
| NCT06701305Healthy · United States | 1 | Completed | Merck | Feb 18, 2025 | 48 |
| NCT06482112Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 2 | Completed | Merck | Jun 27, 2025 | 124 |
| NCT06465186Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more | 2 | Completed | Merck | Aug 3, 2026 | 85 |
| NCT06052566Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Merck | Dec 5, 2024 | 22 |
| NCT05877547Non-alcoholic Fatty Liver Disease · United States, Austria, Belgium and more | 2 | Completed | Merck | Dec 29, 2025 | 381 |
| NCT04944992Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 2 | Completed | Merck | Oct 19, 2022 | 145 |
| NCT03618160Healthy · Japan | 1 | Terminated | Johnson & Johnson | Jun 21, 2019 | 42 |
| NCT03606057Healthy · United States | 1 | Completed | Johnson & Johnson | Feb 8, 2019 | 188 |
| NCT03586843Obesity · United States | 1 | Completed | Johnson & Johnson | Mar 17, 2019 | 52 |
| NCT03586830Obesity · United States | 2 | Completed | Johnson & Johnson | Apr 5, 2019 | 196 |
| NCT03546205Kidney Failure, Chronic · United States | 1 | Completed | Johnson & Johnson | Dec 17, 2018 | 40 |
| NCT03486392Obesity · United States, Belgium, Canada and more | 2 | Completed | Johnson & Johnson | Mar 8, 2019 | 474 |
| NCT03235219Diabetes Mellitus, Type 2 · United States | 1 | Completed | Johnson & Johnson | Feb 19, 2018 | 39 |
| NCT02862431Diabetes Mellitus, Type 2 · Germany | 1 | Terminated | Johnson & Johnson | Nov 29, 2016 | 24 |
How it is read
Names in the registry
- “Efinopegdutide”, 6 entries
- “JNJ-64565111”, 6 entries
- “JNJ-64565111 Dose Level 1”, 2 entries
- “JNJ-64565111 Dose Level 2”, 2 entries
- “JNJ-64565111 Dose Level 3”, 2 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Obesity, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.